Science Immunology

Supplementary Materials

Supplementary Material for:

Natural killer cell–mediated inflammation resolution is disabled in severe asthma

Melody G. Duvall, Cindy Barnig, Manuela Cernadas, Isabell Ricklefs, Nandini Krishnamoorthy, Nicole L. Grossman, Nirav R. Bhakta, John V. Fahy, Eugene R. Bleecker, Mario Castro, Serpil C. Erzurum, Benjamin M. Gaston, Nizar N. Jarjour, David T. Mauger, Sally E. Wenzel, Suzy A. Comhair, Andrea M. Coverstone, Merritt L. Fajt, Annette T. Hastie, Mats W. Johansson, Michael C. Peters, Brenda R. Phillips, Elliot Israel, Bruce D. Levy,* National Heart, Lung, and Blood Institute's Severe Asthma Research Program-3 Investigators

*Corresponding author. Email: blevy{at}

Published 10 March 2017, Sci. Immunol. 2, eaam5446 (2017)
DOI: 10.1126/sciimmunol.aam5446

This PDF file includes:

  • Fig. S1. Flow cytometry gating strategies.
  • Fig. S2. BAL lymphocytes in healthy and asthmatic individuals.
  • Fig. S3. Levels of additional cytotoxic mediators in BALF from healthy and asthmatic individuals.
  • Fig. S4. Systemic triamcinolone does not alter BAL CD4+ T cell number or the ratio of effector CD4+ T cells to NK cells in asthma.
  • Fig. S5. Exposure to dexamethasone or LXA4 changes peripheral blood NK cell phenotype, and LXA4 exposure does not impair NK cell release of cytotoxic mediators.
  • Table S1. Patient number (n) for each experiment.

Download PDF

Other Supplementary Material for this manuscript includes the following:

Files in this Data Supplement: